3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
17
Carcinoma, Non-Small-Cell Lung
9
Squamous Cell Carcinoma of Head and Neck
7
Carcinoma, Hepatocellular
6
Triple Negative Breast Neoplasms
5
Small Cell Lung Carcinoma
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Colorectal Neoplasms
4
Stomach Neoplasms
3
Neoplasm Metastasis
3
Mesothelioma
2
Melanoma
2
Head and Neck Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Merkel Cell
2
Urinary Bladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Neuroendocrine
1
Anophthalmia with pulmonary hypoplasia
1
Interventions
pembrolizumab
91
Gemcitabine
55
Nivolumab
49
Cisplatin
38
atezolizumab
31
Carboplatin
30
avelumab
25
enfortumab vedotin
23
Docetaxel
23
Magnetic Resonance Spectroscopy
18
Ipilimumab
17
Paclitaxel
16
Mitomycin
15
Specimen Handling
14
durvalumab
11
toripalimab
10
sacituzumab govitecan
10
Pemetrexed
10
cabozantinib
9
Taxes
8
vinflunine
7
Cyclophosphamide
7
tislelizumab
6
Injections
6
Bevacizumab
6
pemigatinib
5
fludarabine
5
disitamab vedotin
5
Standard of Care
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Transitional Cell
×
budigalimab
×
Clear all
NCT06632951
2025-08-11
LIVIGNO-3
AbbVie
Phase 2
Active not recruiting
150 enrolled